Additionally, the 36-month beta value for EVH is 1.57. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 7 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EVH is 110.62M and currently, short sellers hold a 10.43% ratio of that float. The average trading volume of EVH on June 25, 2024 was 1.24M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EVH) stock’s latest price update
The stock price of Evolent Health Inc (NYSE: EVH) has dropped by -2.73 compared to previous close of 22.04. Despite this, the company has seen a fall of -1.07% in its stock price over the last five trading days. prnewswire.com reported 2024-06-04 that Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent’s specialty condition management platform through AI-enabled clinical workflow automation Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics Acquisition expected to benefit health plans, clinicians, and members WASHINGTON, June 4, 2024 /PRNewswire/ — Evolent Health, Inc. (“Evolent” or “the Company”), (NYSE: EVH) a company focused on achieving better health outcomes for people with complex conditions, today announced it has entered into an agreement to acquire certain assets of Machinify and the exclusive, perpetual and royalty-free license of Machinify Auth, a proven software platform that leverages the latest advances in artificial intelligence to increase the clinical quality, speed and consistency of the clinical reviews for all specialty conditions. Evolent plans to integrate the Machinify Auth team, software applications and AI capabilities into its leading platform.
EVH’s Market Performance
EVH’s stock has fallen by -1.07% in the past week, with a monthly drop of -6.35% and a quarterly drop of -33.83%. The volatility ratio for the week is 3.01% while the volatility levels for the last 30 days are 4.12% for Evolent Health Inc The simple moving average for the past 20 days is -4.25% for EVH’s stock, with a -24.85% simple moving average for the past 200 days.
Analysts’ Opinion of EVH
Many brokerage firms have already submitted their reports for EVH stocks, with Citigroup repeating the rating for EVH by listing it as a “Buy.” The predicted price for EVH in the upcoming period, according to Citigroup is $40 based on the research report published on April 22, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see EVH reach a price target of $45. The rating they have provided for EVH stocks is “Outperform” according to the report published on March 01st, 2024.
Barclays gave a rating of “Overweight” to EVH, setting the target price at $39 in the report published on January 03rd of the current year.
EVH Trading at -14.44% from the 50-Day Moving Average
After a stumble in the market that brought EVH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.75% of loss for the given period.
Volatility was left at 4.12%, however, over the last 30 days, the volatility rate increased by 3.01%, as shares sank -7.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.73% lower at present.
During the last 5 trading sessions, EVH fell by -0.90%, which changed the moving average for the period of 200-days by -16.18% in comparison to the 20-day moving average, which settled at $22.30. In addition, Evolent Health Inc saw -35.10% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EVH starting from Blackley Seth, who sale 141,000 shares at the price of $26.54 back on Dec 05 ’23. After this action, Blackley Seth now owns 637,645 shares of Evolent Health Inc, valued at $3,741,475 using the latest closing price.
McCarthy Daniel Joseph, the PRESIDENT of Evolent Health Inc, sale 11,000 shares at $30.00 during a trade that took place back on Nov 15 ’23, which means that McCarthy Daniel Joseph is holding 198,333 shares at $330,000 based on the most recent closing price.
Stock Fundamentals for EVH
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.19 for the gross margin
The net margin for Evolent Health Inc stands at -0.05. The total capital return value is set at -0.03. Equity return is now at value -10.17, with -4.22 for asset returns.
Based on Evolent Health Inc (EVH), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at 0.2. The debt to equity ratio resting at 0.76. The interest coverage ratio of the stock is -1.16.
Currently, EBITDA for the company is 46.38 million with net debt to EBITDA at 5.1. When we switch over and look at the enterprise to sales, we see a ratio of 1.42. The receivables turnover for the company is 5.09for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.02.
Conclusion
In conclusion, Evolent Health Inc (EVH) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
